Autopsy report · NCT03138889
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 1 month before it started.
- Ran for about 5 years 2 months before it stopped.
- 162 participants enrolled.
- Results were posted on the registry 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Nektar Therapeutics
- Sponsor type
- Industry
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- NKTR-214; Pembrolizumab; NKTR-214; NKTR-214; Cisplatin; Carboplatin
- Participants
- 162
- Sites
- 38
- Countries
- Australia, France, Germany, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.